

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **February 22, 2017**

**BioSig Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-55473**  
(Commission File Number)

**26-433375**  
(IRS Employer  
Identification No.)

**8441 Wayzata Blvd., Suite 240**  
**Minneapolis, Minnesota**  
(Address of principal executive offices)

**55426**  
(Zip Code)

Registrant's telephone number, including area code: **(763) 999-7330**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

BioSig Technologies, Inc. (the “Company”) intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences a slide presentation, which is attached hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#"><u>Investor Presentation, dated 2017 (furnished herewith pursuant to Item 7.01)</u></a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSIG TECHNOLOGIES, INC.**

Date: February 22, 2017

By: /s/ Kenneth L. Londoner  
Name: Kenneth L. Londoner  
Title: Executive Chairman



**corporate presentation  
2017**



**Symbol: BSGM**

# Disclaimer



This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

# Visibility Leads to Cures

In 1900, a **third of all US deaths** were from pneumonia, tuberculosis and diphtheria

In 2014, **less than 1000** people died from these diseases

Better **visualization** enabled these successes



Today **heart problems** are the **number one cause of death**



BioSig is developing technologies to help doctors better **visualize** abnormal heart rhythms

**There may be a multi-billion dollar potential market for our patent-pending medical visualization technology**


Symbol:BSGM

# Atrial Fibrillation (AFib) Background

## Normal Heart Rhythm



## Atrial Fibrillation (as one example of a complex arrhythmia)



- Rapid/irregular heart rate
- Everyone over 40 has a 1 in 4 lifetime risk
- Complex arrhythmias expensive due to multiple ablation procedures needed
- Affects > 6M in US


Risk of stroke 4-to 5-fold  
(5th leading cause of death in US)

Sources: CDC, <http://www.preventaf-strokecrisis.org/files/files/The%20AF%20Report%2014%20April%202012.pdf>


Symbol:BSGM

# Ventricular Tachycardia (VT)

Normal Heart Rhythm



Ventricular Tachycardia



Symbol:BSGM

- Rapid / irregular heartbeat in the ventricles of the heart
  - Rapidly fatal if not reversed
    - ≈ 450,000 Sudden cardiac deaths in the US annually
      - Can be treated with ablation

Improved signals should enable more precise treatment and less procedures



# Current Diagnosis to Treatment



Medication 


ECG Diagnose

Choose Treatment

BioSig's Focus:  
Improve Diagnosis →  
Increase Ablation Success

EP Study


Ablation



Symbol:BSGM

# Ablation: One Current Solution For Atrial Fibrillation (AFib)

- Catheter inserted into heart
- Scars tissue that harbors abnormal heart rhythm
- The catheter will use either heat or cold to scar the tissue
- When done in the right place AFib stops



**Goal: Improve cardiac signal accuracy to reduce costs; repeat procedures**

(1)[http://journals.lww.com/ajnonline/Fulltext/2015/10000/CE\\_\\_Catheter\\_Ablation\\_of\\_Atrial\\_Fibrillation.25.aspx](http://journals.lww.com/ajnonline/Fulltext/2015/10000/CE__Catheter_Ablation_of_Atrial_Fibrillation.25.aspx)

Symbol:BSGM


# Comparison with Competition

BioSig's PURE EP™ System in **Red**

Competition in **Blue**


**Micro-components revealed**

**Noisy Signal**



**Low amplitude signals revealed**

**Noisy Signal**



Symbol:BSGM

# Large & Fast Growing Market




## EP Devices

Current EP Market is <\$4 B worldwide



## Procedure Growth




- EP Labs: Estimated 5,000 WW; 3,000 in the US
- By 2020, expected 422,000 procedures in the US with over \$3B in revenues

**Driver: Ablation becoming first line of therapy**

Symbol:BSGM

9

# Competitive Landscape EP Recording Devices



~\$1 BILLION  
Installed Base

**Our competitors'  
technology is dated**

Symbol:BSGM

10

## PURE EP System Testimonial

*"The improved resolution may translate to **better ability to pick up specific signals and relate them to specific structure and substrate.**"*

**Samuel J. Asirvatham,  
M.D. Mayo Clinic**

*"The dynamic range of the system is larger - likely will translate into **better ability to see both large and small (frequency and amplitude) signals with similar resolution.** This is a major problem with present systems, where in order to see smaller signals, we have to amplify the signals, and in doing so, we lose the ability to see larger signals without saturating these signals."*

*"The **display options are also more intuitive and flexible.** For example, different filtering can be applied to the same signal and displayed as separate, simultaneous signals. Presently this is not possible with the existing systems to my knowledge."*

MDDI - <http://www.mddionline.com/article/cutting-out-noise-target-arrhythmias-07-08-15>

Symbol:BSGM

11

# Path To Market



Symbol:BSGM

# Upcoming Major Company Milestones



CATEGORY	Q1	Q2	Q3	Q4
PEER REVIEWED PUBLICATIONS	Engineering Journal – 1H 2017 Cardiology Journal – 1H 2017			
ON-GOING CLINICAL TRIALS	Mayo – Advanced Research Initiative Mount Sinai – VT Scar Model    UCLA – Advanced VT Mapping			
INDUSTRY SYMPOSIA		Heart Rhythm Society – May 10-13, 2017		
		EHRA-CARDIOSTIM – June 18-21, 2017		
NEW PATENT APPLICATIONS	Visualization Tools		Recording EP Procedures	
FDA 510(k) CLEARANCE	Submission 1H 2017		FDA Clearance 2H 2017	
UPLIST TO NASDAQ	Uplist to NASDAQ			

Symbol:BSGM



# Board of Directors



<b>Kenneth L. Londoner, MBA</b>	<b>Founder, Executive Chairman, Director;</b> Endicott Management Partners, J & W Seligman & Co
<b>Gregory D. Cash</b>	<b>President, CEO and Director:</b> U.S. Surgical, Boston Scientific, Medtronic
<b>Roy T. Tanaka</b>	<b>Director;</b> Former CEO of BioSense Webster, Johnson & Johnson; Volcano Corp, VytronUS, Coherex Medical
<b>Seth H. Z. Fischer</b>	<b>Director;</b> Current CEO & Dir: Vivus, Inc; Former WW Chairman: Johnson & Johnson, Cardiovascular
<b>Patrick J. Gallagher, MBA</b>	<b>Director;</b> Managing Director Laidlaw & Co.; Kinex Pharma; Founder BDR Research Group, Kidder Peabody
<b>Jeffrey F. O'Donnell, Sr.</b>	<b>Director;</b> CEO, Chair: Trice Medical; Chair: Mela Sciences; Founder: Embrella Cardiovascular
<b>Jerome B. Zeldis, MD, PhD</b>	<b>Director;</b> CEO of Celgene Global Health & Chief Medical Officer of Celgene Corporation; Chairman: Alliqua
<b>David Weild IV, MBA</b>	<b>Director;</b> Founder & CEO: Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance Prudential
<b>Donald E. Foley</b>	<b>Director;</b> CEO & Chair: Wilmington Trust; Sr VP, Treas, & Dir: ITT Corp; Asst Treas: Int'l Paper Co.



Symbol:BSGM

# Proven Management Team



<b>Kenneth L. Londoner, MBA</b>	<b>Founder, Executive Chairman, Director;</b> Endicott Management Partners, LLC, J & W Seligman & Co
<b>Gregory D. Cash</b>	<b>President, CEO and Director;</b> Pres: Argent International, NeuroTherm, Heartsine Tech, Vasomedical, Datascope, Eminent Tech; Mgmt: U.S. Surgical, Boston Scientific, Medtronic
<b>Steve Chaussy, CPA</b>	<b>CFO;</b> Liberski Inc, Anna & Co, Penske Automotive, Ford Hogg and Cobbe
<b>Jay O. Millerhagen, MS, MBA</b>	<b>VP Clinical Research;</b> VP Clinical/Mkt Dev: RESPICARDIA, Inc.; VP/Sr Dir Clinical: St Jude Medical; Dir New Product Planning, Brady Mktg, Heart Failure R&D/Mktg, Bus Alliance Mktg with J&J, GE Healthcare: Boston Scientific
<b>Brian McLaughlin</b>	<b>VP Corporate Finance, Investor Relations;</b> President & COO: Ridgeback Capital; Head of Equity Trading: Sigma Capital; Trader: SAC Capital & JP Morgan & Co.



J.P.Morgan



Symbol:BSGM

# World-Class Scientific Advisory Board



<b>Andrea Natale, MD, Chairman</b>	<b>Executive Medical Director</b> , Texas Cardiac Arrhythmia Institute, St. David's Medical Center
<b>Samuel Asirvatham, MD</b>	<b>Professor of Medicine &amp; Vice Chair of Division of Cardiovascular Diseases</b> , Department of Medicine; program director Clinical Cardiac Electrophysiology Training Program, Mayo Clinic in Rochester, Minnesota
<b>K. L. Venkatachalam, MD</b>	<b>Assistant Professor of Medicine</b> , Division of Cardiovascular Diseases, Mayo Clinic in Jacksonville, Florida
<b>Kalyanam Shivkumar, MD, PhD</b>	<b>Director</b> , UCLA Cardiac Arrhythmia Center; Professor of Medicine & Radiology
<b>Mauricio Arruda, MD</b>	<b>Director</b> , Clinical Electrophysiology & Pacing, University Hospitals Case Medical Center
<b>Vivek Reddy, MD</b>	<b>Director</b> , Cardiac Arrhythmia Service and a Helmsley Trust Professor of Medicine, Mount Sinai Medical Center in New York
<b>Luigi Di Biase, MD, PhD</b>	<b>Senior Researcher at Texas Cardiac Arrhythmia Institute</b> ; Associate Professor, Albert Einstein College of Medicine, Adjunct Professor at the UT Austin



Symbol:BSGM

# Presentations and Manuscripts from Pre-Clinical Studies



Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation

Presented by team from Mayo Clinic at the *13<sup>th</sup> Annual International Dead Sea Symposium (IDSS) in Tel-Aviv* and available online, March 2016 – ***Peer Reviewed***

Enhanced Electrophysiology Recording System

Presented at 38<sup>th</sup> Annual International Conference EMBC 2016, August 2016

– ***Peer Reviewed***

Novel electrophysiology signal recording system enables specific visualization of the Purkinje network and other high frequency signals

JACC Clinical Electrophysiology, Volume 2, Issue 7, Page 850, December 2016

– ***Peer Reviewed***

# PURE EP – Development Path

Collaborating with Leading Centers



# EP Sector M&A Activity



Company	Proof of Concept	Prototype	Clinical Data	CE Mark	FDA	Sales	Acquirer/ Investor	Valuation
<b>HeartWare</b>	•	•	•	•	•	•	Medtronic	<b>\$1.1 Billion</b> June 2016
<b>St. Jude Medical</b>	•	•	•	•	•	•	Abbott	<b>\$25 billion</b> April 2016
<b>Hansen Medical</b>	•	•	•	•	•	•	Auris Surgical Robotics	<b>\$80 million</b> April 2016
<b>Kalila Medical</b> Formed 2010	•	•	•	•	•	•	Abbott	Undisclosed Feb 2016
<b>nContact</b> Formed 2005	•	•	•	•			Atricure	<b>\$149 million</b> Oct 2015
<b>CardioInsight</b> Formed 2006	•	•	•	•	•	•	Medtronic	<b>\$272 million</b> June 2015
<b>Topera Medical</b> Formed 2010	•	•	•	•	•		Abbott	<b>\$350 million</b> Dec 2014
<b>Endosense SA</b> Formed 2003	•	•	•	•		•	St. Jude	<b>\$331 million</b> Aug 2013
<b>Bard EP</b> Division of CR Bard	•	•	•	•	•	•	Boston Scientific	<b>\$275 million</b> Nov 2013
<b>Rhythmia Medical</b> Formed 2004	•	•	•				Boston Scientific	<b>\$410 million</b> Oct 2012

# BioSig Technologies, Inc. (BSGM)



OTCQB: BSGM  
WWW.BIOSIGTECH.COM

Key Company Data	(2/17/17)
Recent price:	\$1.54
52-week range:	\$1.05 - \$2.20
Primary shares i/o:	23.68 million
Float:	11.8 million
Market cap:	\$36.47 million
Headquarters:	Minneapolis, MN

Symbol:BSGM

20

# BioSig Investment Highlights



- **Large & Growing Cardiac Arrhythmia Patient Population ⇒ Ablations Increasing 10%+ Annually**
- **\$4B Total Addressable Market for EP Devices at 10% Growth Annually ⇒ High Demand for New Technologies**
- **World-Class Management Team, Board of Directors & Scientific Advisory Board**
- **Aggressive M&A Activity ⇒ High Growth Sector**
- **Plan to Uplist to NASDAQ in 2017**
- **FDA Submission 1H 2017 ⇒ FDA Clearance 2H 2017**

Symbol:BSGM

21



# Contact BioSig



**Ken Londoner**  
**Founder, Executive Chairman**  
(203) 644-5200  
klondoner@biosigtech.com

**Gregory Cash**  
**President & Chief Executive Officer**  
(612) 309-4747  
gcash@biosigtech.com

**Brian McLaughlin**  
**VP, Corporate Finance & Investor Relations**  
(917) 370-9817  
bmclaughlin@biosigtech.com

This document is being provided on a confidential basis by BioSig Technologies, Inc. solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related documents, the only basis on which subscriptions may be made.

Symbol:BSGM

22

